Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Single-Dose Somapacitan in Children with GHD
NCT00936403Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2009
- Primary completion
- Jul 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of somapacitan in growth hormone deficiency (GHD) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Frequency of Adverse events (AEs). Started Aug 2009; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT00936403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00936403.